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SUMMARY – Permanent immunosuppression is necessary to prevent rejection after kidney 
transplantation. However, it may predispose patients to diff erent conditions and diseases including 
oral lesions. Th e most common benign oral lesions in kidney transplant recipients are gingival hyper-
plasia, oral candidiasis, hairy leukoplakia and saburral tongue. Oral form of Kaposi sarcoma, although 
rarely, can also be seen in kidney transplant patients. In this review, we present the incidence, etiology, 
clinical fi ndings, diagnosis and treatment options for these lesions. For kidney transplant recipients, it 
is important to maintain good oral hygiene and care, as well as regular professional control by the 
dentist. Th is approach can reduce the number and severity of oral lesions.
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Introduction
Kidney transplantation (KT) is the treatment of 
choice for patients with end-stage renal disease. It is 
the most cost-eff ective and improving quality of life 
strategy. In the last 20 years, the number of KT has 
increased, with more than 13 000 cases in the United 
States of America (USA)1 and more than 200 cases in 
Croatia per year (208 KT in 2013)1. Due to improve-
ment in patient selection, kidney preservation, immu-
nosuppression, surgical techniques, diagnosis and 
treatment of complications, as well as in follow up, 
survival of grafts and KT patients has been signifi cant-
ly improved. In the USA, one-year kidney graft sur-
vival is 80%-85% for cadaveric and more than 90% for 
living donor transplants2.
Kidney allograft recipients usually have signifi cant 
comorbidities, have been exposed to dialysis for longer 
period of time, and demand permanent immunosup-
pression. Th erefore, they are liable to diff erent diseases 
including oral lesions. In this review, we present the 
most common benign oral diseases in KT recipients 
and oral form of Kaposi sarcoma.
Gingival Hyperplasia
Gingival hyperplasia (GH) or gingival overgrowth 
is a well known side eff ect of cyclosporine, calcium 
channel blockers such as nifedipine and anticonvul-
sants3,4. Th e reported incidence of drug induced GH 
varies from 8% to 85%, depending on the study popu-
lation and methodology3,5. Although the mechanism 
of drug-induced GH remains unknown and probably 
is multifactorial, recent studies show that cyclosporine 
promotes GH, aff ecting diff erent signaling molecules 
in gingival fi broblasts6. Calcium channel blockers 
change calcium ion fl ux which may infl uence collage-
nase, resulting in changes in collagen production and 
breakdown in gingival fi broblast, leading to collagen 
deposition in gingival tissue7,8. In humans, there is no 
proven connection between GH and patient sex, diag-
nosis before transplantation, dialysis, age at transplan-
tation or time after transplantation, but it has been 
shown that cyclosporine dose and plasma level were 
signifi cant risk factors for development and extent of 
GH. Also, gingival infl ammation and tooth plaque 
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were strongly associated with GH9. Children and ado-
lescents are more prone to this disease than adults10, 
and it is important to note that the patients developing 
severe GH had evidence of GH prior to kidney trans-
plantation11.
Gingival hyperplasia or gum status can be scored in 
three or, better, four grades: grade 0 (normal gum); 
grade 1 or mild GH (slight overgrowth and thickening 
of marginal gum, covering up to 1/3 of the crown); 
grade 2 or moderate GH (moderate gum overgrowth 
covering ½ of the crown), which is the most common 
form; and grade 3 or severe GH (severe gum over-
growth covering 2/3 of the crown, or aff ecting all of 
adhered gum)12. Th e most aff ected are usually labial 
aspects of both superior and inferior anterior teeth13. 
At the beginning of disease, interdental papillae be-
come soft, red nodules which can easily bleed. Progres-
sive hyperplasia extends to labial, buccal, palatal and 
lingual gingiva, later due to fi brotic changes the tissue 
appears pink, fi rm and resilient to palpation. In most 
severe cases, almost whole crown can be covered with 
gum tissue. GH can be painful; it can cause diffi  culties 
on eating and speaking, as well as aesthetic problems.
Although withdrawal of therapy would be the best 
option, it is usually not possible in KT recipient. How-
ever, switching from cyclosporine to the newer immu-
nosuppressive drug tacrolimus can lead to regression 
or complete resolution of GH14. Also, in patients hav-
ing used tacrolimus from the beginning GH was pres-
ent only sporadically15. Complete resolution of GH 
has been shown in adult KT recipients that have been 
treated with metronidazole16, but these results were 
not confi rmed in pediatric population17. Th e treatment 
with azithromycin also showed signifi cant improve-
ment of GH in KT recipients18. Th e exact mechanisms 
how these drugs eff ect GH is not known, but they are 
probably related to their antimicrobial eff ect. Hyper-
plastic tissue can also be surgically removed, either by 
traditional gingivectomy or using laser as a newer, less 
invasive procedure19. Good oral hygiene and oral 
chlorhexidine rinse can be helpful for GH, mainly due 
to reduction in gingival infl ammation and plaque re-
moval20.
Oral Candidiasis
Candida albicans may be present in normal oral 
fl ora in up to 50% of the population. It is the most 
common cause of oral candidiasis (70%-80%), al-
though other Candida species such as Candida gla-
brata and Candida tropicalis can cause this disease as 
well21. Diseases or conditions like immunosuppression, 
which aff ect the host immune system, predispose pa-
tients to candida infections. Furthermore, immuno-
suppression is the most important factor for develop-
ment and progression of oral candidiasis. In KT pa-
tients, Candida dubliniensis and Candida famata cause 
a signifi cant number of cases7,22. Th e reported inci-
dence of oral candidiasis in KT recipients varies from 
4% to 43%23-25. Most commonly infected are the pal-
ate, tongue and buccal mucosa, although any oral mu-
cosal surface can be involved. Th ere are diff erent clini-
cal presentations of the disease, with erythematous, 
pseudomembranous and hyperplastic candidiasis be-
ing the most common types26. Erythematous candidi-
asis can be categorized into acute and chronic atrophic, 
angular cheilitis, median rhomboid glossitis and 
chronic multifocal candidiasis. Erythematous candi-
diasis is presented with erythema of the involved tis-
sue, although atrophic changes and fi ssures can be seen 
as well. Pseudomembranous candidiasis is character-
ized with white-yellow plaques that can be wiped off  
revealing underlying mucosa with erythematous ap-
pearance which may bleed slightly. Th is form of candi-
diasis is most common in immunocompromised pa-
tients. Hyperplastic candidiasis or candidal leukopla-
kia is presented as white lesions, most commonly on 
buccal mucosa, although occasionally focal areas of 
erythema can be seen26.
Diagnosis is usually based on clinical presentation 
and patients are often empirically treated with anti-
fungal medication. To confi rm the disease, laboratory 
testing of clinical specimens have to be done. Samples 
from suspected areas can be obtained for culture using 
Sabouraud’s agar plate, for exfoliative cytology or bi-
opsy. On microscopy, candida hyphae or blastospores 
can be seen. For prevention and treatment of the dis-
ease, regular oral hygiene is mandatory. Rinsing of oral 
cavity with 0.1% hypochlorite or chlorhexidine solu-
tion is advisable27. Antifungal drugs such as nystatin 
can be applied topically or systemic therapy with fl u-
conazole or itraconazole can also be used.
Saburral Tongue
Saburral tongue is clinically presented as a yellow-
ish-white superfi cial layer on the back of the tongue, 
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resembling pseudomembranous candidiasis, but can-
not be scraped off . Filiform papillae enlargement can 
also be seen. In the study by de la Rosa Garcia et al., 
suburral tongue was found in 22% of patients with 
KT28. Th e etiology of this condition is unknown, al-
though some authors report on the association be-
tween suburral tongue and poor oral hygiene29. Fur-
thermore, the accumulation of anaerobic bacteria in 
the subgingival plaque has been shown, suggesting 
that they may be important for this condition.
Hairy Leukoplakia
Leukoplakia is defi ned as a white adherent patch or 
plaque that can occur on oral mucosa. Oral hairy leu-
koplakia is a form of leukoplakia which presents as a 
white, hairy appearing lesion on one or both lateral 
borders of the tongue, which cannot be scraped off . It 
may also extend to buccal, labial or palatal mucosa. 
Th is condition is related to immune status and most 
patients are immunocompromised30. Hairy leukopla-
kia can be seen in 8%-11% of patients with KT7,31. 
Histologically, severe hyperkeratosis and acanthosis 
with virally infected epithelial cells can be seen. Ep-
stein-Barr virus was isolated from these cells and has 
been implicated as a causative factor for hairy leuko-
plakia32. Candida albicans can also be related to this le-
sion. Hairy leukoplakia is usually asymptomatic and 
has no malignant potential, therefore, no treatment is 
needed in most cases. However, antiviral medication 
such as acyclovir or gancyclovir, topical podophyllin or 
even surgical excision can be used, although recurrence 
is common as long as the cause of immunosuppression 
is present32.
Kaposi Sarcoma
Kidney transplant recipients have a signifi cantly 
higher frequency of malignant lesions as compared 
with general population and the risk is increasing with 
each year after transplantation. Kaposi sarcoma ac-
counts for 5.7%-11% of all neoplasms arising after 
KT33,34. It is an angiogenic tumor the development of 
which can be divided into three phases, i.e. the patch 
or macular stage, the plaque, and the nodular stage35. 
Histopathologically, the disease is characterized by 
endothelium-lined vascular spaces and spindle-shaped 
cells36. Kaposi sarcoma can be seen as oral lesion (pal-
ate and gingiva) after renal transplantation, and it is 
important to know that in oral presentation, Kaposi 
sarcoma may mimic gingival hyperplasia. Th e etiology 
of the disease is unknown, although Kaposi sarcoma 
has been strongly related to immunosuppression and 
human herpes virus 837. Th e disease is usually asymp-
tomatic, although the lesion itself can be seen in the 
mouth. In KT patients with Kaposi sarcoma, immuno-
suppression with cyclosporine and mycophenolate 
mofetil should be replaced with an mTOR inhibitor 
(sirolimus or everolimus), and the disease can be treat-
ed with surgery, irradiation and chemotherapy (pacli-
taxel)38.
Discussion and Conclusion
Approximately two-thirds of KT patients have at 
least one oral mucosa lesion28. Th e most common oral 
mucosa lesions that can be found after thorough oral 
examination of renal transplant recipients are gingival 
hyperplasia, oral candidiasis, hairy leukoplakia and sa-
burral tongue39. All these lesions can be related to im-
munosuppressive drugs, either as their side eff ect or as 
a direct consequence of the patient immune status. Th e 
most common drugs used for immunosuppression af-
ter KT are calcineurin inhibitors (cyclosporine and 
tacrolimus), steroids, mycophenolate mofetil and 
mTOR inhibitors (mammalian target of rapamycin).
For KT patients, good oral hygiene and care, regu-
lar professional control by the dentist, as well as opti-
mal treatment for diff erent oral lesions including 
change of immunosuppressive therapy when necessary, 
can reduce the number and severity of oral lesions.
Oral health is not only important for KT patients, 
but also for general population. It has recently been 
shown that diff erent chronic oral conditions such as 
periodontitis can be related to diff erent systemic dis-
eases, e.g., anemia of chronic disease40. Posttransplant 
anemia is a chronic condition related to erythropoietin 
substitution and blood transfusion. Investigation of 
oral status in KT patients with anemia may give addi-
tional data on the possible link between oral diseases 
and chronic diseases such as anemia41.
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Sažetak
PROMJENE U USNOJ ŠUPLJINI NAKON TRANSPLANTACIJE BUBREGA
K. Levarda-Hudolin, T. Hudolin, N. Bašić-Jukić i Ž. Kaštelan
Nakon transplantacije bubrega bolesnici moraju biti na trajnoj imunosupresiji, što ih čini osjetljivima za različita stanja i 
bolesti uključujući oralne lezije. Najčešće dobroćudne oralne lezije kod bolesnika s transplantiranim bubregom su hiperpla-
zija gingive, oralna kandidijaza, vlasasta leukoplakija i obloženi jezik. Oralna forma Kaposijevog sarkoma također se, iako 
rijetko, može vidjeti kod bolesnika s transplantiranim bubregom. Donosimo pregled incidencije, etiologije, kliničke slike, 
dijagnoze i liječenja ovih lezija. Kod bolesnika s transplantiranim bubregom važna je redovita skrb za oralno zdravlje uz 
održavanje oralne higijene te redovite posjete liječnicima dentalne medicine, što sve može smanjiti broj i ozbiljnost oralnih 
lezija.
Ključne riječi: Bubreg, transplantacija; Oralne bolesti; Gingivalna hiperplazija; Kandidijaza, oralna; Leukoplakija, vlasasta; 
Jezik, obloženi; Sarkom, Kaposijev
